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There is an urgent need for new, safer, and effective
treatments for the diseases caused by the protozoan
parasites Trypanosoma brucei, Trypanosoma cruzi,
and Leishmania spp. In the search for more effective
drugs to treat these ‘neglected diseases’ researchers
have chosen to reassess the therapeutic value of
nitroaromatic compounds. Previously avoided in drug
discovery programs owing to potential toxicity issues, a
nitro drug is now being used successfully as part of a
combination therapy for human African trypanosomia-
sis. We describe here the rehabilitation of nitro drugs for
the treatment of trypanosomatid diseases and discuss
the future prospects for this compound class.
The urgent need for new drugs for trypanosomatid
diseases
The genus Kinetoplastida is responsible for diseases such
as human African trypanosomiasis (HAT), Chagas disease
(CD), and the leishmaniases (Table 1). Collectively, these
‘neglected’ diseases (see Glossary) cause more than
120 000 fatalities annually and the loss of 5 000 000
disability-adjusted life years [1]. Some of the poorest areas
of the world are afflicted by these vector-borne parasites,
and the accompanying economic burden provides an ob-
stacle to improving human health [2]. Current treatments
for these diseases are not ideal, with issues such as unac-
ceptable toxicity [3], acquired drug resistance [4], pro-
longed hospitalization, and cost [1]. Therefore, there is a
compelling need for new treatments.
Nitroaromatic drugs
Compounds containing a nitroaromatic group (Box 1) are
used to treat a wide variety of indications including Par-
kinson’s disease, angina, and insomnia [5–7]. Additionally,
several nitroaromatics are used as anti-infective agents,
including drugs to treat parasitic infections [8,9]: for
example, nitazoxanide is approved for giardiasis and
Review
Glossary
Ames test: a widely employed Salmonella-based cell assay used in medicinal
chemistry projects to determine whether a given compound is mutagenic.
Deazaflavin (F420): an unusual 8-hydroxy-5-deazaflavin cofactor closely related
to FMN.
Deazaflavin-dependent nitroreductase (Ddn): a nitroreductase from Mycobac-
terium tuberculosis which catalyzes the deazaflavin-dependent reduction of
nitroimidazoles such as PA-824.
Drugs for Neglected Diseases Initiative (DNDi): an independent, not-for-profit
drug research and development organization. DNDi research focuses on the
area of neglected diseases, in particular on leishmaniasis, human African
trypanosomiasis, and Chagas disease (http://www.dndi.org).
Drug-like: a small molecule which falls within a predefined range of
physicochemical parameters. The parameters differ slightly depending upon
the indication and the desired mode of administration. The most commonly
applied parameters for an orally available drug are: molecular weight <500
Daltons, partition coefficient log P <5, 5 hydrogen bond donors, and 10
hydrogen bond acceptors. In addition, particular structural motifs are
commonly excluded.
Drug repurposing: investigating the effectiveness of an existing drug for a new
indication.
Effective concentration 50 (EC50): the concentration of drug required to kill 50%
of parasites in an in vitro assay.
Flavin mononucleotide (FMN): a cofactor in many oxidoreductase reactions.
Liquid chromatography–mass spectrometry (LCMS): an analytical technique
wherein the components of a mixture are separated by high performance
liquid chromatography (HPLC) coupled to a mass spectrometer (and usually a
UV detector).
Neglected disease: a disease for which there is a disproportionately low level
of investment and research into the development of treatments relative to the
size of the affected population. Neglected diseases typically affect developing
countries, and the at-risk populations have insufficient purchasing power to
allow the profitable development of therapeutics.
Nitroreductase (NTR) enzymes: a family of FMN- or FAD-dependent enzymes
capable of metabolizing nitroaromatic compounds. NTRs utilize NADH or
NADPH as a reductive cofactor. The NTRs are subdivided into two classes
depending upon their reaction mechanism.
Pro-drug: a compound that is administered in an inactive/less than fully active
form that requires conversion to its active form through a normal metabolic
process.
Small molecule: a low molecular weight compound (usually below 500
Daltons). The term is usually used to distinguish small chemical compounds
from larger biomolecules – for example, peptides.
Structural alert: a medicinal chemistry term used to describe a chemical
moiety, or functional group, that is known to impart undesirable properties to a
molecule – for example, a group known to be reactive or unstable in vivo.
Type I nitroreductases: FMN-dependent NTRs that catalyze the reduction of
nitroaromatic compounds by a two-electron mechanism. Type I NTRs are
oxygen-insensitive, being able to carry out reactions under both aerobic and
anaerobic conditions.
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Keywords: trypanosomatids; nitroaromatics; nitroreductase; pro-drugs; bioactivation.Type II nitroreductases: NTRs that catalyze the reduction of nitroaromatic
compounds by a one-electron mechanism. In the presence of oxygen, this
reduction leads to the production of superoxide anions.
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Table 1. Trypanosomatid diseases
Disease Human African trypanosomiasis (HAT) Chagas disease Visceral leishmaniasis (VL)
Causative agents Trypanosoma brucei gambiense
Trypanosoma brucei rhodesiense
Trypanosoma cruzi Leishmania donovani
Leishmania infantum
Areas of endemicity West and central Africa (T. b. gambiense)
East and southern Africa (T. b.
rhodesiense)
Central and South America India, Bangladesh, Nepal, Sudan,
Ethiopia, and Brazil
Deaths per annum 30 000 [1] 10 000 [67] 50 000 [68]
Pathology and
symptoms
Early stage: parasites proliferate in the
blood and lymphatic systems. This
results in patients generally feeling
unwell, experiencing indeterminate
symptoms such as headaches
Late stage: parasite invasion of the
central nervous system results in
progressive neurological breakdown.
Fatal if untreated
Acute: a general feeling of being unwell
accompanies the acute phase following
infection.
Indeterminate stage/chronic: a long,
asymptomatic, indeterminate phase can
follow. Inflammatory responses to residual
parasites can induce progressive and
sometimes fatal inflammatory damage to
the heart, esophagus, colon, or other
organs [69]
Initial skin lesions at the site of
infection. 2–8 months following
infection migration of parasites to
the liver and the spleen results in
gross inflammatory reactions
within the viscera. Fatal if untreated
[69]
Current front-line
therapies
Early stage: pentamidine and suramin
Late stage: melarsoprol, eflornithine
monotherapya and NECT (nifurtimox-
eflornithine combination therapy)a
Acute: nifurtimox and benznidazole
Indeterminate and chronic stages: no
standard treatments
Amphotericin B and lipid
formulations
Miltefosine
Pentavalent antimonials
Paromomycin
aNot effective against T. b. rhodesiense infection.
Review Trends in Parasitology June 2014, Vol. 30, No. 6cryptosporidiosis [10]; metronidazole for trichomoniasis,
giardiasis, and amoebiasis [11]; and nifurtimox for CD and
HAT.
The presence of a nitro group in a compound can result
in several toxicity issues including carcinogenicity, hepa-
totoxicity, mutagenicity, and bone-marrow suppression
[12,13]. Consequently, some nitro drugs are avoided whereBox 1. What is a nitroaromatic compound?
A nitro group is a chemical functional group containing a nitrogen
atom bound to two oxygen atoms and one carbon atom which
connects the group to the rest of the molecule. The nitrogen atom in a
nitro group is positively charged, and the two oxygen atoms share a
negative charge. A nitro group can be drawn in several ways;
commonly the whole group is abbreviated as NO2. Alternatively, the
nitro group can be represented by the structures (A) or (B) in Figure I.
A nitroaromatic compound is a molecule in which one or more
nitro groups are directly attached to an aromatic ring system. For
example, nitrobenzene (C), 2-nitrofuran (D), and 5-nitroimidazole (E)
in Figure I.
Chemically, the nitro group possesses a unique combination of
properties; it is strongly electron-withdrawing, small, polar, and can
form hydrogen bonds [70]. In addition, the nitro group can be
bioactivated by enzymatic reduction to give reactive species (Box 2,
Figure 2). In many cases these reactive species are responsible for
the biological effects of nitro drugs [15], in which case the
nitroaromatic compound is acting as a pro-drug.
O
O
(A) (B)
(C) (D) (E)
O
O
H
N
N
O2N
O2NO2NO2N
O
N N
+ +
–
–
TRENDS in Parasitology 
Figure I. Alternative nitro group representations and examples of
nitroaromatics.
290there are suitable alternatives; for example, other anti-
biotics are preferred to chloramphenicol [14]. In addition,
the risk of nitro drug toxicity can be reduced by monitoring
for side effects; for instance, liver function is measured in
those taking tolcapone [5]. Many nitroaromatics require
bioactivation (Box 2) to exert their action. However, un-
wanted bioactivation can also cause toxic side effects [15].
Thus, the very feature which makes the nitro group indis-
pensable for drug action may also render it unsuitable for
administration. Identifying the human enzymes which
activate nitro drugs may provide strategies to reduce
toxicity. For example, nifurtimox is an alcohol dehydroge-
nase 2 (ALDH2) substrate, and it has been proposed that
coadministration with ALDH2 inhibitors could reduce tox-
icity [16].
Pharmaceutical companies have increased their use of
compound metrics and predictors of drug-likeness  in an
attempt to reduce failures in the drug development pro-
cess [17]. One result of this is that compounds containing
nitro groups are routinely removed from screening collec-
tions because the functionality is classified as a ‘structur-
al alert’ [13,18]. Likewise, medicinal chemists are
unlikely to synthesize nitroaromatics during the drug
development process. This will reduce the number of
nitroaromatics under development and may result in
missed opportunities.
Nitro drugs and the trypanosomatids: an historical
perspective
The chemotherapeutic potential of nitroaromatic com-
pounds for HAT was first recognized in the 1950s. The
5-nitrofuran derivative nitrofurazone demonstrated cura-
tive properties against experimental T. brucei gambiense
infections in mice [19,20]. These findings, combined with
the knowledge that the drug was both central nervous
system penetrant and orally bioavailable, prompted clini-
cal trials of nitrofurazone for the treatment of both T. b.
gambiense and T. b. rhodesiense patients [20–22]. Notably,
Box 2. Reduction of nitro groups by NTR enzymes
In biological systems, nitro groups can undergo enzymatic reduction,
which can proceed by either a one or two electron mechanism [71].
Nitro group reduction can be catalyzed by NTR enzymes, of which
there are two classes. Type I (oxygen-insensitive) NTRs perform two-
electron reductions, and type II (oxygen-sensitive) NTRs perform one-
electron reductions [72] (Figure I).
Sequential two-electron reduction of nitro groups produces amines
via nitroso and hydroxylamine intermediates. The nitroaromatics and
amines are relatively stable. However, the nitroso and hydroxylamine
intermediates can react with biomolecules to exert toxic and
mutagenic effects [15,73]. In addition, there is evidence to suggest
that hydroxylamines are converted to reactive nitrenium ions, which
can react with DNA [73].
One-electron reduction of a nitro group produces a nitro radical
anion. This anion is not stable, and under aerobic conditions is
reoxidized back to a nitro group by molecular oxygen, which is in turn
reduced to form a reactive superoxide anion. This process is termed
the ‘futile cycle’, and in some cases is responsible for the toxic effects
of nitro compounds. In the absence of oxygen, two nitro radical
anions can undergo a disproportionation reaction to form one
molecule of the parent nitroaromatic and a nitroso compound. It
has been proposed that this process may produce nitroso compounds
in biological systems [74].
O
O2
O2
Oxygen
–
2e– reducon
(type I NTR)
1e– reducon
(type II NTR)
2e– reducon
(type I NTR)
2e– reducon
(type I NTR)
O–
O OH
NH NH2Ar Ar
AmineHydroxylamine
NAr
Nitroso
O
O–NAr
Superoxide
anion
Nitro radical
anion
Nitro radical
anion
Nitro
(Ar = aromac moiety)
N
+
+
Ar
•
•
O
O–NAr
•
Nitro
O
O–NAr
TRENDS in Parasitology 
Figure I. One- and two-electron reduction of nitroaromatics.
Review Trends in Parasitology June 2014, Vol. 30, No. 6many of the patients recruited in these trials were refrac-
tory to the current therapies using pentamidine, suramin,
and melarsoprol. In the absence of alternative therapies for
these ‘hopeless’ patients, nitrofurazone elicited cure rates
of 50%. However, the neuropathological toxicity associ-
ated with high doses of nitrofurazone led to the trials being
suspended. The efficacy of nitrofurazone was also assessed
in animal models of CD [23,24] and in both cutaneous and
visceral leishmaniasis (VL) [25]. In all cases, nitrofurazone
demonstrated only moderate levels of in vivo activity and
was not further pursued.
In the wake of nitrofurazone, several nitroaromatic
compounds, including the nitrofuran furaltadone and the
nitroimidazole metronidazole [8,19], were found to have
anti-trypanosomal activity, but their development was
abandoned owing to low efficacy and neurotoxicity. How-
ever, continued interest in the therapeutic potential of this
compound class led to the discovery of the 5-nitrofuran
nifurtimox (Figure 1). Identified by Bayer in in vitro
screens against T. cruzi, nifurtimox was marketed under
the brand name Lampit, principally for use in the treat-
ment of acute CD. For many years nifurtimox was consid-
ered the front-line therapy for this indication. Nifurtimox
is no longer prescribed in Brazil, Chile, Uruguay, or the
USA owing to reports of gastrointestinal tract side effects,genotoxicity, low efficacy against particular T. cruzi
strains, and the emergence of neurotoxicity similar to that
encountered during nitrofurazone development.
Nifurtimox has also shown activity against HAT, and
the drug is effective against both the acute and chronic
stages of T. b. gambiense infection. Efficacy was first
demonstrated in rat models and then in a limited clinical
trial in four European patients [26]. Subsequent trials with
various nifurtimox regimens [27,28] revealed that cure
rates were variable (30–80%), with toxicity accompanying
higher doses and prolonged treatment [29]. Consequently,
nifurtimox was not approved as a monotherapy for second-
stage HAT and is used primarily to treat patients refrac-
tory to existing therapies. Despite the problems associated
with its use, nifurtimox has a place in HAT chemotherapy
in nifurtimox–eflornithine combination therapy (NECT)
[30].
The current drug of choice for acute-stage CD is the 2-
nitroimidazole benznidazole (Figure 1). Benznidazole has
been used in the treatment of CD for more than 40 years,
producing long-term parasitological cure in 70% of acute-
stage patients. Like nifurtimox, benznidazole is orally
administered with treatment consisting of 5–10 mg/kg/
day for 30–60 days. Although benznidazole is considered
to be tolerated better than nifurtimox, a range of serious291
N+
O
O
–O
–O
–O
O
O
O
O
(R)-PA-824
O
OCF3
OCF3
O–S
N
O
O
O
O
OO
S
S
S
R
R
R
R
O
NH
N
N
+
+
N
N
Fexinidazole
Fexinidazole sulfoxide
Fexinidazole sulfone
N
N
N
–O
O
O
O
DNDI VL-2098
+
N
N N
NN
Nifurmox Benznidazole
N+
TRENDS in Parasitology 
Figure 1. Selected anti-trypanosomatid nitroaromatics and their metabolites. Nitroaromatic compounds used to treat, or are in development for, trypanosomatid diseases.
For fexinidazole, both the parent compound and the two metabolites resulting from in vivo oxidation are shown.
Review Trends in Parasitology June 2014, Vol. 30, No. 6side effects are associated with its use, including dermato-
logical reactions [31], agranulocytosis, and polyneuropathy
[9]. Owing to these serious adverse effects, recommended
drug schedules are frequently not completed, providing
ideal conditions for the emergence of drug resistance. In
addition to toxicity, Ames assays demonstrate that benz-
nidazole is mutagenic [32].
The value of benznidazole in treating chronic-stage CD
is controversial. Although some reports show efficacy in
treating chronic infections in mice [33], at present there is
insufficient evidence to support routine use of the drug in
humans. With this in mind, a multi-centre, double-blind,
placebo-controlled trial of benznidazole in patients with
chronic Chagas heart disease is underway [34]. Without a
viable alternative, hope lies in finding evidence for a
beneficial and definitive effect in these patients.
Reassessing the chemotherapeutic potential of
nitroaromatic compounds
Despite the valid safety concerns surrounding nitroaro-
matic compounds, there is continued interest in their use
as therapeutics, particularly for infectious diseases and
cancer. In these instances the aim is to develop compounds
that are selectively toxic such that the compound kills the
infectious agent/cancer cells without harming the host/
normal cells [12].
Nitroaromatics can exert cellular toxicity via mecha-
nisms that cannot be replicated by standard ‘drug-like’
molecules (Box 2). Therefore, inclusion of nitroaromatic
compounds in screening collections increases the probabil-
ity of finding a screening hit, especially in cell-based/phe-
notypic assays. Given the urgent need for new drugs to
treat trypanosomatid diseases, and the efficacy of existing
nitro drugs for these indications, several laboratories have
shown a willingness to identify and develop nitroaromatic
anti-trypanosomatid compounds [35–37]. The Drugs for
Neglected Diseases initiative (DNDi) has actively chosen292to investigate nitroaromatic compounds [38]. Their inves-
tigations have proved fruitful, resulting in a trypanosoma-
tid portfolio that contains several nitroaromatics.
Many of the nitroaromatics in development result from
drug repurposing programs. For example, the anti-para-
sitics nitazoxanide and nifurtimox are now in clinical trials
for hepatitis C [10] and pediatric neuroblastoma [39],
respectively. In a drug repurposing project the compound
under investigation has already completed some clinical
trials, and therefore the safety and pharmacokinetic prop-
erties have been assessed thoroughly [40]. Accordingly,
this strategy can both expedite and lower the cost of the
drug discovery process. The risk of a project is reduced
significantly by using a nitroaromatic proven safe previ-
ously; not all nitro drugs are toxic, but it is impossible to be
certain that a compound developed de novo will be safe.
Moreover, the potential cost savings make the repurposing
of drugs and clinical candidates against neglected diseases
particularly attractive. Indeed, the use of nifurtimox to
treat HAT [30] and the development of fexinidazole for VL
[41] are examples of repurposing nitroaromatics for trypa-
nosomatid diseases.
Nitro drugs and the trypanosomatids: drug rediscovery
The combination of eflornithine with nifurtimox was first
evaluated for the treatment of late-stage T. b. gambiense
infection in 2001 as part of a clinical trial comparing three
drug combinations: melarsoprol and eflornithine, melarso-
prol with nifurtimox, and eflornithine with nifurtimox [42].
The study was aimed at addressing the myriad of disad-
vantages of existing anti-trypanosomal drugs. The ratio-
nale was that using drugs in combination would reduce the
likelihood of drug resistance emerging and allow reduced
drug doses to be used, thus reducing toxicity without
compromising efficacy. Unfortunately, this clinical trial
was interrupted on ethical grounds owing to high drug-
related mortality reported in the melarsoprol arms of the
Review Trends in Parasitology June 2014, Vol. 30, No. 6trial. However, the combination of eflornithine and nifur-
timox appeared to be well tolerated and demonstrated
sufficiently promising efficacy to warrant further investi-
gation. This drug combination, known as NECT, was
assessed in a randomized Phase III non-inferiority trial
[30]. The cure rates reported with NECT in this study
(96.5%) were comparable to those seen with eflornithine
monotherapy, with patients suffering fewer adverse
effects. In the combination therapy, intravenous eflor-
nithine is given at 200 mg/kg every 12 h for 7 days, with
nifurtimox being administered orally 3 times daily for 10
days. NECT has many advantages over eflornithine mono-
therapy; specifically the reduced frequency and duration of
eflornithine infusions is seen as highly beneficial in terms
of cost, logistics, and human resources in areas of poverty.
NECT was added to the Model Lists of Essential Medicines
of the World Health Organization in 2009 and is now being
used to treat more than 60% of cases of late-stage T. b.
gambiense HAT (http://www.doctorswithoutborders.org).
Around the time of the development of NECT, the
nitroimidazole megazol also demonstrated promising an-
ti-trypanosomal activity. A megazol–suramin combination
was curative in stage 2 HAT rodent models [43,44]. Al-
though subsequently abandoned owing to genotoxicity
[45], the perceived potential of megazol at this time, along-
side the success of nifurtimox in NECT, encouraged DNDi
to initiate a comprehensive search for nitroaromatics with
anti-trypanosomatid activity. As a result, 700 selected
compounds were assayed for anti-parasitic activity. Among
the hit compounds was the 5-nitroimidazole fexinidazole
(Figure 1), first described in 1978 [46]. In its first incarna-
tion, fexinidazole demonstrated potent in vitro and in vivo
activity against trichomonads, Entamoeba histolytica, T.
cruzi, and T. brucei [47]. When coadministered with sur-
amin, fexinidazole was found to effectively cure the stage 2
mouse model of HAT. However, the clinical development of
this drug was not pursued, largely due to the ingrained
prejudice against nitroaromatic compounds at that time.
Reassessment of the pharmacological and toxicological
profile of fexinidazole established the compound as a prom-
ising candidate for both the acute and chronic stages of
HAT [38]. Significantly, a barrage of assays to detect
toxicity, carried out both in vitro and in vivo assays,
confirmed that fexinidazole is non-genotoxic to mammali-
an cells. In 2009, fexinidazole became the first new trypa-
nosomatid disease clinical candidate for three decades, and
is currently undergoing Phase III trials. It is hoped that
this nitroimidazole will become the first orally available
drug for both stages of HAT.
To date, nitroaromatics have not been widely used in the
treatment of the leishmaniases. However, in light of the
promise shown by fexinidazole for HAT, the compound was
assessed for its potential to treat VL [41]. Winkelmann and
Raether had hypothesized that fexinidazole could be me-
tabolized in vivo to the sulfoxide and/or sulfone (Figure 1)
[46]. Subsequent pharmacokinetic profiling of blood from
mice orally dosed with fexinidazole confirmed that this was
the case [41]. Indeed, the metabolism is rapid, and the
sulfoxide and sulfone blood concentrations exceed that of
fexinidazole, strongly suggesting that the metabolites are
the therapeutically relevant species in vivo. Interestingly,both metabolites of fexinidazole were active against L.
donovani amastigotes grown in macrophages, whereas
the parent compound was inactive [41]. The reasons for
this discrepancy in activity are not fully understood. Fex-
inidazole was subsequently found to be a potent inhibitor of
Leishmania infection in vivo. Administration of a once-
daily oral regimen of fexinidazole (200 mg/kg) over 5 days
suppressed infection in a mouse model of VL by approxi-
mately 98%, a potency comparable to that seen with the
current frontline anti-leishmanial miltefosine. In light of
these findings, patients are being recruited for a Phase II
proof-of-concept study to evaluate the suitability of fexini-
dazole as a treatment for VL in Sudan (http://
www.dndi.org). The versatility of fexinidazole has been
further demonstrated by its efficacy as an effective oral
treatment of acute and chronic experimental CD caused by
benznidazole-susceptible, partially resistant, and resis-
tant T. cruzi [48]. This raises the possibility that fexinida-
zole could act as a panacea for all three trypanosomatid-
related diseases.
Nitro drugs and the trypanosomatids: in the pipeline
Encouraged by the success of NECT and the undoubted
potential of fexinidazole, there is now a willingness to
investigate further the chemotherapeutic potential of nitro
drugs for trypanosomatid diseases. Many of the toxic
effects observed after the administration of nitro drugs
in the past have resulted from prolonged treatment. The
Target Product Profiles (TPP, Table 2) developed for all
three trypanosomatid diseases have now stipulated that
treatment regimens should be of short duration. With this
in mind, researchers and clinicians are now more open to
the use of this compound class for the treatment of trypa-
nosomatid diseases.
Several recent reports have described nitroaromatics
with promising anti-trypanosomatid activity. For in-
stance, a series of 5-nitro-2-furancarboxylamides showed
potent cidal activity against T. brucei in vitro. Signifi-
cantly, the most potent of these compounds was 1000-
fold more potent than nifurtimox against bloodstream-
form parasites [35]. Similarly, a subset of aziridinyl-2-4-
dintrobenzyl compounds possessing a 5-amide substitu-
ent were identified with cidal activity against L. dono-
vani intracellular amastigotes (EC50 <100 nM) [37]. The
(R)-enantiomer of the novel nitroimidazopyran agent,
(S)-PA-824, currently in Phase II clinical trials for tuber-
culosis, is a potent inhibitor of L. donovani, both in vitro
and in vivo. In the murine model of VL, (R)-PA-824
administered orally at 100 mg/kg twice daily resulted
in a virtual cure, suppressing infection by >99% [49].
Furthermore, an additional nitroimidazole, DNDI-VL-
2098, is at an advanced stage of preclinical development
for use in the treatment of VL (http://www.dndi.org).
Collectively, these findings suggest that nitroaromatics
may play a significant role in the future treatment of
these diseases.
Nitroaromatic compounds: mechanism of action
Given the prominence of nitroaromatics in the drug dis-
covery pipelines of several diseases, concerted efforts are
now being made to elucidate their mechanisms of action.293
Table 2. Ideal target product profiles (TPP) for trypanosomatid diseasesa
Human African trypanosomiasisb Visceral leishmaniasisc Chagas diseasec
Active against all subspecies Active against all species Active against all strains
Active against melarsoprol-refractory strains Active against resistant strains Active against nitrofuran- and
nitroimidazole-resistant T. cruzi strains
Efficacy against early- and late-stage disease Compatible for combination therapy Superior to benznidazole and effective
for both chronic and late-stage disease
Oral formulation Oral formulation Oral formulation
Curative in 14 days (late stage) Once daily oral treatment (10 days) Once daily oral treatment (30 days)
Cheaper than current treatments <$10/course No cost defined
Safe in pregnancy Safe in pregnancy and in
immunocompromised patients
No genotoxicity; no teratogenicity; no
negative inotropic effect; significant pro-
arrhythmic potential
Stable in tropical conditions Stable in tropical conditions Stable in tropical conditions
aAs an aid to future drug discovery, key features desired from any drug to be used in the treatment each of the neglected diseases have now been collated and defined as
TPPs.
bAdapted from [75].
cAdapted from http://www.dndi.org.
Review Trends in Parasitology June 2014, Vol. 30, No. 6As for any small-molecule inhibitor, nitroaromatic com-
pounds can exert their biological effects by binding to one
or more molecular targets (usually proteins), and as a
result produce the phenotype of interest, which is cell
death in the case of anti-parasitics. If this is the case,
the nitro group acts like any other functional group by
contributing directly or indirectly to one or more target–
ligand binding interactions. Moreover, the fact that
nitroaromatics can be enzymatically reduced (Box 2)
allows them to exert cellular toxicity via additional mech-
anisms, as demonstrated for the nitro drugs used to treat
trypanosomatid diseases [50,51].
Several early studies suggested that trypanosomes
bioactivate nifurtimox by a one-electron, type II nitrore-
ductase (NTR)-dependent mechanism, and that the result-
ing oxidative stress was responsible for the observed
cytotoxicity (reviewed in [9]). However, it is now apparent
that bioactivation of nifurtimox, benznidazole, and fexini-
dazole is mediated by type I NTR enzymes (Box 2)
[37,41,52]. These recent findings supersede previous stud-
ies implicating other enzymes such as trypanothione re-
ductase in the activation of nitroaromatics (reviewed in
[9]). Trypanosomatids are unusual in that they possess a
bacterial-like type I NTR [52] for which there is no mam-
malian homolog. Therefore, the selective toxicity observed
for these inhibitors may be due to the presence of a specific
parasitic bioactivating enzyme which is absent from the
host. Unsurprisingly, nitroaromatics selectively activated
by the bacterial-like NTR are also Ames positive [32]. This
brings into question the suitability of this assay for asses-
sing the mutagenic potential of this compound class within
a mammalian host. By recombinantly expressing the cata-
lytic domains of trypanosomatid NTRs, a detailed exami-
nation of the mechanism of nitro drug bioactivation is now
possible [50,51].
Incubation of nifurtimox with T. brucei (Tb)NTR or T.
cruzi (Tc)NTR leads to the formation of an unsaturated
open-chain nitrile product (Figure 2A) [50]. No intermedi-
ate metabolites were observed in this transformation.
However, it can be inferred that the nitro group has
undergone two sequential two-electron reductions, giving
first a nitroso and then a hydroxylamine intermediate.294Subsequent furan ring-opening with loss of water would
lead to the observed unsaturated open-chain nitrile.
TcNTR reduces the carbon–carbon double bond of this
product metabolite to give a saturated open-chain nitrile,
but only following prolonged incubation. Therefore, this
additional reduction is unlikely to be physiologically rele-
vant and is hence not involved in the drug mode of action.
The unsaturated open-chain nitrile is also toxic against
bloodstream-form T. brucei parasites in vitro, with a po-
tency similar to that measured for nifurtimox (EC50 values
of 5.3 mM and 2.9 mM, respectively [50]); thus the NTR-
dependant production of the unsaturated open-chain ni-
trile could possibly be responsible for cell death following
treatment with nifurtimox. Interestingly, the unsaturated
open-chain nitrile is equipotent against T. brucei and
mammalian cells in vitro, whereas nifurtimox itself is
10-fold more potent against T. brucei, consistent with
the paradigm that drug selectivity is achieved through
selective bioactivation by the parasite. The mechanism
by which the unsaturated open-chain nitrile causes cell
death is undetermined. However, the unsaturated open-
chain nitrile contains a Michael acceptor, a chemical moi-
ety that is known to react with sulfhydryl groups in pro-
teins or other biomolecules [53]. Therefore, it can be
hypothesized that the unsaturated open-chain nitrile irre-
versibly inhibits one or more essential proteins by cova-
lently binding to an accessible and/or activated cysteine
residue(s), leading to cell death.
The mechanisms underlying resistance to nifurtimox in
T. brucei were recently assessed using a genome-scale RNA
interference target sequencing (RITseq) screen [54]. In this
elegant study, eight genes were identified as being strongly
associated with nifurtimox resistance. Of these eight
genes, six directly or indirectly reaffirmed the dominant
role of the NTR in nifurtimox activation.
Benznidazole also serves as a substrate for TcNTR and
TbNTR [51]. As for nifurtimox, the nitro group undergoes
two sequential two-electron reductions to give a hydroxyl-
amine intermediate (Figure 2B), which was detected by
liquid chromatography–mass spectrometry (LCMS) follow-
ing incubation with recombinant NTR and NADH. Unlike
nifurtimox, the reduced benznidazole does not undergo a
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Figure 2. Mechanism of nitroreductase (NTR)-mediated bioactivation of nitroaromatic compounds. (A) Nifurtimox undergoes two sequential NTR-catalyzed reductions,
followed by ring opening to give a toxic unsaturated open-chain nitrile. Tb, Trypanosoma brucei; Tc, Trypanosoma cruzi. (B) The nitro group of benznidazole is reduced to
the hydroxylamine by NTR. Subsequently, a series of non-enzymatic transformations leads to a dihydro-dihydroxy product, which can release glyoxal. (C) Unusually,
MtbDdn [deazaflavin (F420)-dependent nitroreductase (Ddn) of Mycobacterium tuberculosis (Mtb)] does not reduce the nitro group of (S)-PA-824. Instead, the first step of the
bioactivation involves reduction of the C2–C3 bond of the bicyclic imidazooxazine ring system. The unstable product of this reduction is protonated and then undergoes a
des-nitrification reaction to give des-nitro-PA-824, with the concomitant production of nitrous acid. Some structures have been abbreviated for clarity. Compounds in
square brackets are not experimentally detected. Adapted from [9,61].
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transformations convert the hydroxylamine intermediate
into a 4,5-dihydro-4,5-dihydroxyimidazole (Figure 2B)
[55,56]. Note, both the cis and trans isomers of this diol
were detected by LCMS analysis of the reaction mixture
[51]. In aqueous solution these dihydro-dihydroxyimida-
zoles are known to exist in equilibrium with glyoxal and a
substituted guanidine product (Figure 2B) [57]. Glyoxal is
a highly toxic, reactive dialdehyde which is capable of
chemically modifying proteins, lipids, and nucleotides
[58]. Therefore, it was hypothesized that the formation
of glyoxal is responsible in part for the anti-trypanosomal
action of benznidazole. In support, addition of guanosine to
the reaction mixture leads to the formation of a guanosine–
glyoxal adduct [51]. However, the production of glyoxal
from dihydro-dihydroxyimidazoles is extremely slow [57],
meaning that glyoxal production is unlikely to be the sole
cytotoxic mechanism.
Laboratory-generated nifurtimox-resistant T. brucei
are cross-resistant to fexinidazole in vitro and in vivo
[59], suggestive of a common mechanism of action for
these two compounds. Additionally, transgenic L. donovaniparasites overexpressing L. major NTR are approximately
20-fold more sensitive to fexinidazole in vitro [41,60]. These
observations are consistent with the hypothesis that the
bioactivation of fexinidazole is dependent upon NTR enzymes
in trypanosomatids. However, it is currently unknown which
fexinidazole reduction product(s) is responsible for the cidal
activity of the compound.
Under anaerobic conditions the anti-mycobacterial ac-
tion of (S)-PA-824 is dependent upon reductase-mediated
bioactivation [61]. This reduction is catalyzed by an un-
usual deazaflavin (F420)-dependent nitroreductase (Ddn)
[61,62]. Incubation of (S)-PA-824 with recombinant Myco-
bacterium tuberculosis (Mtb)Ddn leads to the formation of
multiple products, the most abundant being (S)-des-nitro-
PA-824 (Figure 2C) [61,63]. This bioactivation also pro-
duces nitric oxide. Transcriptional profiling suggests that
respiratory poisoning by nitric oxide is responsible for the
anti-mycobacterial action of (S)-PA-824 [64]. The L. dono-
vani genome does not contain a MtbDdn homolog. There-
fore, it was hypothesized that the type I NTR might
instead be responsible for bioactivation of (S)- and
(R)-PA-824 in Leishmania. Transgenic L. donovani295
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sensitivity to (S)-, or (R)-PA-824 [49], and a close analog of
PA-824 is not a substrate for TbNTR [51]. These results
demonstrate that (S)- and (R)-PA-824 are not activated by
the trypanosomatid type I NTR. Both (R)- and (S)-des-
nitro-PA-824 are inactive against L. donovani in vitro [49],
confirming that the nitro group is important for the anti-
leishmanial activity of PA-824. If the mechanism of action
of PA-824 does involve bioactivation, then this putative
reduction is mediated by an as-yet unidentified enzyme(s).
Under aerobic conditions the anti-mycobacterial action of
(S)-PA-824 involves inhibition of mycolic acid biosynthesis
[65]. L. donovani do not possess the mycolic acid biosyn-
thetic pathway, meaning that this mechanism cannot be
implicated in the anti-leishmanial activity of PA-824.
Nitro drugs: implications of widespread use
The simultaneous development of multiple nitroaromatics
for the trypanosomatid diseases potentially has serious
implications. It is considered undesirable to have several
compounds with a shared mode of action under develop-
ment for a single indication. Such a scenario leaves the
pipeline vulnerable to multiple compound failures associ-
ated with a single mechanism. Specifically, parasites re-
sistant to one nitroaromatic can be cross-resistant to a
second; for example, nifurtimox-resistant T. brucei are
cross-resistant to fexinidazole [59]. In this case resistance
is largely due to their common NTR-mediated mode of
action. This brings into question the rationale of develop-
ing further NTR-activated nitroaromatic compounds for
the treatment of trypanosomatid-related diseases. There-
fore, it is important to determine if new anti-trypanoso-
matid nitroaromatics are NTR-activated early in
development. The primary physiological function of trypa-
nosomatid NTRs is not to reduce exogenous nitroaro-
matics. NTR is essential in Leishmania and T. brucei,
and is required for virulence in T. cruzi [52,60,66]. RITseq
data suggest that this essential role is linked to ubiquinone
biosynthesis [54]. The essentiality of NTR has implications
for drug resistance, and suggests that NTR is itself a
potential drug target.
The target product profile (TTP) for VL (Table 2) stipu-
lates that newly developed drugs should be suitable for
combination therapy. Clearly, the partner drugs in any
combination therapy must have distinct modes of action.
Despite both being nitroimidazoles, (R)-PA-824 and fex-
inidazole do not share a common mechanism of action [49].
Therefore, a single mutation is unlikely to confer resis-
tance to both compounds. In combination, fexinidazole and
(R)-PA-824 have an additive effect against L. donovani in
vitro. This raises the possibility that these two nitroaro-
matics could be co-developed as a VL oral combination
therapy.
Concluding remarks and future perspectives
The launch of NECT in 2009 not only heralded the first new
therapy for HAT in over three decades, but also demon-
strated that nitro drugs could be used to treat trypanoso-
matid diseases safely and effectively. As a result there has
been a marked increase in the number of nitroaromatic
compounds in development for these diseases, including296for the first time a clinical candidate for VL. During the
same period our understanding of the anti-trypanosomal
mechanisms of action of nitro drugs has substantially
improved.
By using recombinant proteins it has been possible to
characterize the bioreduction of nifurtimox and benzni-
dazole at the molecular level. Our understanding is
incomplete, and the anti-leishmanial mechanism(s) of
action of (R)-PA-824 and DNDI-VL-2098 remain to be
determined. Defining the mechanism(s) of action of these
compounds should be a priority. A more complete under-
standing of how these nitroimidazoles kill parasites
will inform drug combination strategies, and may
identify novel drug targets/mechanisms of cytotoxicity
which could be exploited by de novo target-based drug
discovery.
Recent research has revealed the potential of nitroaro-
matics to treat neglected diseases and has eroded the long-
held prejudice against them. Mindful of the risks associat-
ed with this compound class, future drug development
should proceed with caution rather than disregarding
nitroaromatics out of hand.
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